Eli Lilly said on Monday its oral weight-loss drug Foundayo significantly reduced breathing interruptions during sleep in obese adults with moderate-to-severe obstructive sleep apnea, meeting the main goal of a late-stage study.
Foundayo reduced breathing interruptions by up to 44% on average at 52 weeks as measured by a diagnostic scale used to measure the severity of sleep apnea, Lilly said.
Obstructive sleep apnea is a sleep disorder in which the upper airway repeatedly collapses during sleep, lowering oxygen levels and disrupting breathing.
